Optimal Route for Tranexamic Acid in Diabetics and Obese Patients Undergoing Primary Total Knee Arthroplasty - a Data from Randomized Study.

PURPOSE OF THE STUDY To determine the optimal strategy for tranexamic acid (TXA) administration in diabetic patients, smokers and obese patients (BMI > 30 kg/m2) undergoing primary total knee arthroplasty (TKA). MATERIAL AND METHODS The total of 400 consecutive patients indicated for primary TKA were randomised into 4 basic groups with different TXA administration regimens. Group 1 (IV1) had a single intravenous dose (15 mg TXA/kg) applied prior to skin incision. Group 2 (IV2) got two intravenous doses (15 mg TXA/kg): one prior to skin incision and one subsequently 6 hours after the first dose. Group 3 (TOP) had 2 g TXA in 50 ml of saline irrigated topically at the end of the surgery. Group 4 (COMB) combined IV1 and TOP regimens. We monitored the amount of total blood loss (TBL), haemoglobin drop, use of blood transfusions (BTs), and complications in each patient. Follow-up period was one year postoperatively. RESULTS In the group of diabetic patients (n = 87; 21.7%) the lowest TBL was observed in the order: IV1, IV2 > COMB > TOP. In the obese patients (BMI > 30 kg/m2; n = 242; 60.5%), TBL was significantly lower in the intravenous regimens (IV1: p = 0.002; IV2: p = 0.005, respectively) than in the TOP regimen. In the smoking patients (n = 30; 7.5%), TBLs were significantly lower in the order: IV1 > IV2 > COMB > TOP. DISCUSSION Individualised approach to prevention and therapy is a recent trend, also because comorbidities significantly affect the result of the intervention. In the case of diabetes, obesity and smoking, there is a proven link to early post-operative infections, mainly due to poorer innate immunity. It is conceivable, though, that the occurrence of infectious complications is also contributed to by larger hematomas or hemarthroses which are largely preventable. CONCLUSIONS In the diabetic and obese patients (BMI > 30 kg/m2), the combined topical/intravenous TXA application and two intravenous doses of TXA interventions were shown to be the most effective. However, no evidence of superiority of any of the TXA administration routes was obtained in the smokers. None of the TXA protocols was associated with a higher incidence of complications or early reoperation following TKA surgery. Key words: tranexamic acid, topical application, intravenous application, combined administration, diabetes, obesity, BMI, smoking, blood loss, hidden blood loss, total knee arthroplasty, complications.

[1]  P. Clarke,et al.  Co-Morbidities and Sex Differences in Long-Term Quality-of-Life Outcomes among Patients with and without Diabetes after Total Knee Replacement: Five-Year Data from Registry Study , 2019, Journal of clinical medicine.

[2]  A. Siddiqi,et al.  Tranexamic Acid Reduces Transfusion Rates in Obese Patients Undergoing Total Joint Arthroplasty. , 2019, Surgical technology international.

[3]  M. Kudelka,et al.  Smoking, Preoperative Activity, and Waiting Time for the Surgery Could Predict the Risk of Early Reoperation in Total Knee Arthroplasty , 2018, Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca.

[4]  D. Jevsevar,et al.  The Efficacy of Tranexamic Acid in Total Knee Arthroplasty: A Network Meta-Analysis. , 2018, The Journal of arthroplasty.

[5]  Yuangang Wu,et al.  The efficacy and safety of combined administration of intravenous and topical tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials , 2018, BMC Musculoskeletal Disorders.

[6]  Joong Il Kim,et al.  Combined use of topical intraarticular tranexamic acid and rivaroxaban in total knee arthroplasty safely reduces blood loss, transfusion rates, and wound complications without increasing the risk of thrombosis , 2018, BMC Musculoskeletal Disorders.

[7]  T. K. Kim,et al.  What is the Ideal Route of Administration of Tranexamic Acid in TKA? A Randomized Controlled Trial , 2017, Clinical orthopaedics and related research.

[8]  Dae-Hee Lee,et al.  Intravenous versus topical tranexamic acid administration in primary total knee arthroplasty: a meta-analysis , 2017, Knee Surgery, Sports Traumatology, Arthroscopy.

[9]  C. Bezold,et al.  Diabetes 2030: Insights from Yesterday, Today, and Future Trends , 2017, Population health management.

[10]  N. Shah,et al.  Combined Administration of Systemic and Topical Tranexamic Acid for Total Knee Arthroplasty: Can It Be a Better Regimen and Yet Safe? A Randomized Controlled Trial. , 2016, The Journal of arthroplasty.

[11]  A. Rodríguez-Arias,et al.  Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial , 2015, Archives of Orthopaedic and Trauma Surgery.

[12]  K. Oremuš Tranexamic acid for the reduction of blood loss in total knee arthroplasty. , 2015, Annals of translational medicine.

[13]  K. Anderson,et al.  Factors That Impair Wound Healing. , 2012, The journal of the American College of Clinical Wound Specialists.

[14]  L. Good,et al.  Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. , 2003, British journal of anaesthesia.

[15]  P. Holtom,et al.  Periprosthetic Total Hip Infection: Outcomes Using a Staging System , 2002, Clinical orthopaedics and related research.

[16]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[17]  W. Maloney,et al.  Elevated Body Mass Index Is Associated With Early Total Knee Revision for Infection. , 2017, The Journal of arthroplasty.